Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Ontario K1A 0K9, Canada.
J Epidemiol Community Health. 2011 Mar;65(3):191-8. doi: 10.1136/jech.2008.085597. Epub 2010 Jul 13.
Biomonitoring is used increasingly as an indicator and quantitative measure of exposure; however, there is a large gap in interpreting and communicating biomonitoring results to study participants. Two separate, national biomonitoring initiatives are under way in Canada; the household recruitment-based Canadian Health Measures Survey (CHMS) and the clinic recruitment-based Maternal-Infant Research on Environmental Chemicals (MIREC) Study. The CHMS provides participants with the option to receive all their results, but this option is not provided to MIREC participants. The approach to reporting results to participants depends on the availability of reference ranges and guidelines for which tissue concentrations may be interpreted as being elevated or associated with increased health risks, how participants are recruited, unique vulnerabilities of the population, legislation governing access to personal information, and decisions of research ethics committees. It is the researchers' responsibility to present the best case for their approach and, once the decision has been made, to inform participants about access to their results through the consent process.
生物监测越来越多地被用作暴露的指标和定量衡量标准;然而,在向研究参与者解释和传达生物监测结果方面存在很大差距。加拿大正在进行两项独立的国家生物监测计划;基于家庭招募的加拿大健康测量调查 (CHMS) 和基于诊所招募的母婴环境化学研究 (MIREC)。CHMS 为参与者提供了接收所有结果的选择,但 MIREC 参与者没有此选择。向参与者报告结果的方法取决于参考范围和指南的可用性,这些指南可用于解释组织浓度升高或与健康风险增加有关,参与者如何招募,人群的独特脆弱性,管理个人信息访问的立法,以及研究伦理委员会的决定。研究人员有责任为其方法提出最佳案例,一旦做出决定,就通过同意过程告知参与者访问其结果的途径。